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abstract
PURPOSE The Children’s Oncology Group trial ACNS0121 estimated event-free survival (EFS) and overall
survival for children with intracranial ependymoma treated with surgery, radiation therapy, and—selectively—
with chemotherapy. Treatment was administered according to tumor location, histologic grade, and extent of
resection. The impacts of histologic grade, focal copy number gain on chromosome 1q, and DNA methylation
proﬁles were studied for those undergoing surgery and immediate postoperative conformal radiation therapy
(CRT).
METHODS ACNS0121 included 356 newly diagnosed patients (ages 1 to 21 years). Patients with classic
supratentorial ependymoma were observed after gross total resection (GTR). Those undergoing subtotal re-
section received chemotherapy, second surgery, and CRT. The remaining patients received immediate
postoperative CRT after near-total resection or GTR. CRT was administered with a 1.0-cm clinical target volume
margin. The cumulative total dose was 59.4 Gy, except for patients who underwent GTR and were younger than
age 18 months (who received 54 Gy). Patients were enrolled between October 2003 and September 2007 and
were observed for 5 years. Supratentorial tumors were evaluated for RELA fusion; infratentorial tumors, for
chromosome 1q gain. Classiﬁcation of posterior fossa groups A and B was made by methylation proﬁles.
RESULTS The 5-year EFS rates were 61.4% (95% CI, 34.5% to 89.6%), 37.2% (95% CI, 24.8% to 49.6%), and
68.5% (95%CI, 62.8% to 74.2%) for observation, subtotal resection, and near-total resection/GTR groups given
immediate postoperative CRT, respectively. The 5-year EFS rates differed signiﬁcantly by tumor grade (P =
.0044) but not by age, location, RELA fusion status, or posterior fossa A/posterior fossa B grouping. EFS was
higher for patients with infratentorial tumors without 1q gain than with 1q gain (82.8% [95% CI, 74.4% to
91.2%] v 47.4% [95% CI, 26.0% to 68.8%]; P = .0013).
CONCLUSION The EFS for patients with ependymoma younger than 3 years of age who received immediate
postoperative CRT and for older patients is similar. Irradiation should remain the mainstay of care for most
subtypes.
J Clin Oncol 37. © 2019 by American Society of Clinical Oncology
INTRODUCTION
Ependymomas vary in clinicopathologic features,
molecular characteristics, and lethality. In children,
ependymomas commonly arise at midline or lateral
compartments of the posterior fossa.1 Incidence is
highest in children younger than 5 years of age. In-
consistent manifestation of clinical symptoms can lead
to diagnosis delay, extension of local tumor, and as-
sociation with critical neural and vascular structures.2
Historically, age and tumor location were prognostic
factors for treatment selection. Extent of tumor re-
section was limited to avoid morbidity and reduced the
adjuvant radiation therapy (RT) and chemotherapy
effectiveness. RT was avoided because of its somatic,
endocrine, and cognitive impacts. Two age-based
approaches were taken: (1) children age 3 years or
younger were treated with surgery, multiagent con-
ventional chemotherapy, and RT delayed by 1 to
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2 years or until tumor progression occurred; and (2)
children older than age 3 years were treated with combined
modality therapy and postoperative conventional irradiation
with or without combination chemotherapy.3-6
Use of immediate high-dose postoperative conformal RT
(CRT) was investigated in children as young as 12 months
of age.7 CRT showed promise to reduce radiation exposure
to normal tissues and to limit complications.8 To better
improve local tumor control, methods to optimize the extent
of resection before irradiation, including second surgery,
were implemented.9 The beneﬁt was clearly demonstrated
in a trial that showed increased tumor control rates and
cognitive sparing in pediatric patients who received
CRT.10,11 For patients who received immediate post-
operative CRT, 7-year event-free survival (EFS) and overall
survival (OS) were 76.9% and 85%, respectively. Sub-
sequent adverse effects were reduced, and effects on
hearing and the function of endocrine and other systems
could be predicted by radiation dosimetry.12-14
The ACNS0121 trial was activated in 2003 by the Children’s
Oncology Group to validate use of immediate postoperative
CRT and an aggressive surgical approach in pediatric
ependymoma. ACNS0121 was designed to estimate the
local control and pattern of failure in children with com-
pletely resected, classic (differentiated), supratentorial lo-
calized ependymoma after surgery; to estimate the rate of
complete resection with second surgery after chemother-
apy for children; to estimate the local control and pattern of
failure for children with localized ependymoma treated with
three-dimensional CRT using an anatomically deﬁned
1-cm clinical target volume (CTV); to determine the inﬂu-
ence of histologic grade on time to progression after CRT;
and to determine the effect of focal copy number gains or
losses and genomic proﬁling on outcome.15
In a major departure from previous strategies, ACNS0121
was, to our knowledge, the ﬁrst cooperative group trial to
use immediate postoperative irradiation for newly di-
agnosed children age 3 years or younger with ependy-
moma. The trial was the ﬁrst, also, to our knowledge, to
investigate the rate and pattern of failure in patients with
ependymoma treated according to rigorously deﬁned target
volume deﬁnitions and a minimal CTV margin. Herein, we
report patient outcomes by treatment and stratum, RELA
fusion and chromosome 1q status, and ependymoma
molecular subgroup.
METHODS
Eligibility
Patients with histologically conﬁrmed nonmetastatic in-
tracranial ependymoma were eligible for enrollment within
56 days of initial surgical resection. Age at enrollment was
older than 1 year and younger than 21 years. Magnetic
resonance imaging of the brain and spine was required to
conﬁrm the extent of disease and resection. Patients
previously treated with chemotherapy or RT were not eli-
gible. Informed consent and assent were obtained
according to institutional guidelines.
Treatment Regimens and Stratiﬁcation
Protocol treatment was based on extent of resection, tumor
location, and histologic grade. The protocol included three
treatment regimens and four strata (Fig 1).
Surgery
Multiple resections before enrollment were permitted.
Gross tumor resection 1 (GTR 1) was deﬁned as no visible
residual tumor identiﬁed under the operating microscope
and no evidence of disease in postoperative neuroimaging.
GTR 2 was deﬁned as microscopically visible residual tu-
mor identiﬁed under the operating microscope and no
evidence of disease in postoperative neuroimaging. Near-
total resection (NTR) was deﬁned as residual tumor evident
on postoperative neuroimaging with thickness or nodularity
measuring 0.5 cm or smaller in the greatest dimension.
Subtotal resection was deﬁned as residual tumor mea-
suring greater than 0.5 cm on postoperative imaging.
Pathology and Molecular Analyses
Enrollment was based on institutional diagnosis. Patients in
stratum 1 underwent immediate pathology review. Other
patients underwent central pathology review within 5 days
of enrollment. Tumors were classiﬁed and graded
according to the 2007 WHO criteria. Molecular analyses
were performed as described in the Data Supplement.
Radiation Therapy and Chemotherapy
Conformal or intensity-modulated photon and proton
therapy using passive scattering methods was allowed.
Only 20 patients were treated with passively scattered
proton therapy in this study. Gross tumor volume included
the postoperative tumor bed and residual tumor; the CTV
included an anatomically deﬁned margin of 1.0 cm sur-
rounding the gross tumor volume; and the planning target
volume included a geometric margin of 0.3 to 0.5 cm
surrounding the CTV. The CTV was meant to include
subclinical microscopic disease. The planning target vol-
ume was meant to account for variation in daily treatment.
The prescribed total dose was 59.4 Gy, using conventional
fractionation of 1.8 Gy per day. Patients younger than
18 months with GTR 1 or GTR 2 received 54 Gy. Patients in
stratum 2 received two cycles of chemotherapy, which
began within 21 days of enrollment; included one cycle of
vincristine, carboplatin, and cyclophosphamide and one
cycle of vincristine, carboplatin, and oral etoposide; and
lasted approximately 7 weeks.
Response and Evaluation
Required neuroimaging and follow-up information are
described in the Data Supplement. A modiﬁed version of
RECIST was used to evaluate responses. Additional in-
formation about response is in the Data Supplement.
2 © 2019 by American Society of Clinical Oncology
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Cycle A Cycle B
Week 0 1 2 3 4 5 6
Day 1 2 8 1 8 15 22
Cycle A Vincristine
(1.5 mg/m2/dose IV)
X
Carboplatin
(375 mg/m2/dose IV)
X
Cyclophosphamide
(1,000 mg/m2/dose IV)
X                X
Mesna
(200 mg/m2/dose IV)
X                X
Filgrastim
(5 µg/kg/day SC or IV) Daily until ANC > 1500 µl
Cycle B Vincristine
(1.5 mg/m2/dose IV) 
X X
Carboplatin
(375 mg/m2/dose IV) 
X
Etoposide
(50 mg/m2 day PO)
Daily days 1-21 (oral)
Ependymoma
institutional pathology review
Rapid central pathology review
supratentorial primary tumor location
Observation
Cycle A: vincristine + carboplatin +
   cyclophosphamide
Cycle B: vincristine + carboplatin + etoposide
Duration: 7 weeks
Conformal radiation therapy
Clinical target volume: 1.0 cm
Extent of resection: STR
Any histologic grade
Any location
Extent of resection: NTR/GTR2
Any histologic grade
Any location
Extent of resection: GTR 1
Anaplastic histology: supratentorial
Any histologic grade: infratentorial
Extent of resection: GTR 1
Differentiated histology
Supratentorial
Response evaluation (PD/SD/PR/CR)
ResectableUnresectable
Second surgery
Conformal radiation therapy:
clinical target volume: 1.0 cm
A
B
STRATUM 4STRATUM 3STRATUM 2STRATUM 1
Chemotherapy:
FIG 1. (A) Protocol schema and (B) chemotherapy schema. ANC, absolute neutrophil count; CR, complete response; CTV, clinical target volume; GTR,
gross total resection; IV, intravenous; NTR, near-total resection; PD, progressive disease; PO, oral; PR, partial response; SC, subcutaneous; SD, stable
disease; STR, subtotal resection.
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Common Toxicity Criteria, version 2.0, was used for toxicity
and performance reporting, and adverse events of grades 3
and 4 were reported to the Children’s Oncology Group
database. This study did not include uniform digital
treatment planning data submission, which limited evalu-
ation of radiation dose to the brainstem and other critical
normal tissue volumes.
Statistical Analyses
EFS was deﬁned as time to disease progression, disease
relapse, occurrence of a second neoplasm, or death as a
result of any cause measured from the time of study en-
rollment. The product-limit method estimated EFS and OS
probability. The log-rank test compared survival curves.
The McNemar test tested the agreement in pathology.
Cumulative incidence of local failure was deﬁned as the
time to local failure measured from the date of patient
enrollment. Distant failure, second malignancy, or death
before local failure were considered as competing events.
Cumulative incidence of distant failure was deﬁned as time
to distant failure measured from the date of patient en-
rollment. Local failure, second malignancy, or death before
distant failure were considered as competing events.16
RESULTS
Patients and Eligibility
From October 2, 2003 to September 28, 2007, the study
enrolled 378 pediatric patients from 115 institutions. The
median age was 5.6 years (range, 1.01 to 21.01 years), and
108 (28.6%) were age 3 years or younger. The eligible
study group had 356 patients: 150 (42.12%) were women
or girls, and 206 (57.87%) were men or boys. Information
about eligibility and misdiagnosis are in the Data Supple-
ment. Diagnosis was classic ependymoma in 215 patients
(60.39%) and was anaplastic ependymoma in 141 patients
(39.61%). Tumor location was infratentorial in 258,
supratentorial in 96, and transtentorial in two patients.
Outcomes by Treatment
At a median follow-up time of 7.89 years (range, 0.09 to
11.00 years), the 5-year EFS and OS were 62.7% (95% CI,
57.4% to 70.0%) and 83.8% (95% CI, 79.7% to 87.9%),
respectively (Fig 2). Overall responses and toxicities were
reported by stratum 2 or combined strata 3 and 4 and are
available in the Data Supplement.
Stratum 1 included 11 eligible patients. The 5-year EFS was
61.4% (95% CI, 33.2% to 89.6%). Local control was
achieved in six patients (54.55%); local failure occurred in
four patients (36.36%), and local and distant failure oc-
curred in one patient (9.09%). The 5-year OS was 100%.
Stratum 2 included 64 eligible patients. The 5-year EFS was
37.2% (95% CI, 24.8% to 49.5%). Local control was
achieved in 28 patients (47.46%); local failure occurred in
27 patients (45.76%). Local and distant failure occurred in
four patients (6.78%), and distant failure occurred in ﬁve
patients (8.47%). Second surgery occurred in 39% of
patients. For those undergoing second surgery, the 5-year
EFS was 50.5% (95% CI, 30.3% to 70.7%) compared with
28.5% (95% CI, 14.2% to 42.8%) for those not undergoing
second surgery (P = .1163; Appendix Fig A1, online only).
The 5-year OS was 70.2% (95% CI, 58.2% to 82.2%) for
patients in stratum 2.
Stratum 3 included 118 eligible patients. The 5-year EFS
was 67.3% (95% CI, 58.5% to 76.1%). Local control was
achieved in 88 patients (74.58%); local failure occurred in
27 patients (22.88%). Local and distant failure occurred in
three patients (2.54%), and distant failure occurred in 13
patients (11.02%). The 5-year OS was 83.3% (95% CI,
76.2% to 90.4%).
Stratum 4 included 163 eligible patients. The 5-year EFS
was 69.5% (95% CI, 62.1% to 76.9%). Local control was
achieved in 129 patients (79.14%) patients; local failure
occurred in 30 patients (18.4%). Local and distant failure
occurred in four patients (2.45%), and distant failure oc-
curred in 13 patients (7.98%). The 5-year OS was 88.3%
(95% CI, 83.0% to 93.6%). When data from strata 3 and 4
for those who received immediate postoperative irradiation
(n = 281), were combined, the 5-year EFS and OS rates
were 68.5% (95% CI, 62.8% to 74.2%) and 86.2% (95%
CI, 81.9% to 90.6%), respectively.
Outcomes by Tumor Grade and Age
The difference in agreement of institutional and central
review by theMcNemar test was not signiﬁcant (P = .6374).
The 5-year EFS was 74.6% (95% CI, 67.5% to 81.7%) for
patients with classic ependymoma and was 60.7% (95%
CI, 51.5% to 69.9%) for those with anaplastic ependy-
moma treated with immediate postoperative irradiation (P =
.0044; Fig 3).
The 5-year EFS rates were 62.9% (95% CI, 51.9% to
73.9%) and 70.5% (95% CI, 63.8% to 77.2%) for patients
younger than age 3 years versus age 3 years or older,
respectively, at enrollment who were treated with imme-
diate postoperative irradiation (P = .2295). The respective
OS rates for those age groups were 87.4% (95% CI, 79.6%
to 95.2%) and 85.8% (95% CI, 80.7% to 90.9%; P =
.6904; Appendix Fig A2).
Outcomes by RELA Fusion, 1q Gain, and PFA/
PFB Subgrouping
The interphase ﬂuorescence in situ hybridization analysis
identiﬁed RELA fusion in 30 (77%) of 39 supratentorial
tumors. There were no signiﬁcant differences in EFS, OS, or
pattern of failure by fusion status. Also, there were no
signiﬁcant differences in EFS, OS, or pattern of failure
between 23 patients with RELA fusion–positive tumors
treated with surgery and immediate postoperative irradia-
tion and ﬁve patients with non-RELA fusion–positive tumors
who received similar treatment.
4 © 2019 by American Society of Clinical Oncology
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The interphase ﬂuorescence in situ hybridization analysis
detected gain of 1q in 24 (20%) of 121 patients with
infratentorial tumors: ﬁve who received treatment on
stratum 2, and 19 who received immediate postoperative
irradiation. For patients in stratum 2, there was no asso-
ciation between 1q gain status and failure pattern or EFS;
however, the 5-year OS was 20% (95% CI, 0.0% to 44.7%)
for those with 1q gain versus 84.6% (95% CI, 65.8% to
100.0%) for those without 1q gain (P = .0189). For patients
who received immediate postoperative irradiation, the
5-year EFS rates were 82.8% (95% CI, 74.4% to 91.2%)
versus 47.4% (95% CI, 26.0% to 68.8%) for those without
and with 1q gain, respectively (P = .0013; Fig 4). The
respective OS rates were 91.3% (95% CI, 85.0% to 97.8%)
versus 68.4% (95% CI, 48.2% to 88.6%; P = .0028). There
was a signiﬁcant association between local and distant
failure patterns and 1q gain (P = .0101). The 5-year cu-
mulative incidence of local failure was 31.6% (95%CI, 9.8%
to 53.4%) versus 12.3% (95% CI, 5.1% to 19.5%) for those
with and without 1q gain, respectively (P = .054); the cu-
mulative incidence for distant failure was 21.1% (95% CI,
2.2% to 40.0%) versus 6.1% (95% CI, 0.9% to 11.3% for
those with andwithout 1q gain, respectively (P= .040; Fig 5).
The patients in stratum 2 (n = 18) and in the combined
strata 3 and 4 (n = 100) were classiﬁed according to PFA
(posterior fossa group A)/PFB (posterior fossa group B)
subgrouping (Data Supplement). No signiﬁcant associa-
tions between PFA/PFB subgrouping and failure pattern,
EFS, or OS for either treatment existed. Outcomes of pa-
tients who received treatment on strata 3 and 4 were
comparable with those of the subset who contributed to the
PFA/PFB analysis. The 5-year EFS and OS rates were
76.6% (95% CI, 68.0% to 85.2%) and 87.8% (95% CI,
81.1% to 94.5%), respectively.
We evaluated 101 patients who received surgery and im-
mediate postoperative CRT for combined effects of 1q gain
andPFA/PFB grouping onEFS (P= .0011) andOS (P= .0119).
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FIG 2. (A) Event-free survival (EFS) and (B) overall survival (OS) for study cohort and (C) EFS and (D) OS by stratum: S1, stratum 1; S2, stratum 2; S3,
stratum 3; S4, stratum 4. CT, chemotherapy; GTR, gross total resection;; NTR, near-total resection; STR, subtotal resection.
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Differences were most pronounced between those with the
PFA subgroup and 1q gain versus those with the PFA
subgroup and no 1q gain: The 5-year EFS was 35.7% (95%
CI, 12.8% to 58.6%) versus 81.5% (95% CI, 71.5% to
91.5%; P = .0005; Appendix Fig A3), respectively; the
5-year OS was 64.3% (95% CI, 40.6% to 88.0%) versus
91.6% (95% CI, 84.3% to 98.9%; P = .0019), respectively.
Table 1 lists estimates of EFS and OS at 5, 7, and 10 years
for selected outcomes.
Second Malignancies
Seven patients had second malignancies. Second
malignancies were distributed by stratum across stratum 2
(n = 2), stratum 3 (n = 1), and stratum 4 (n = 4). The
cumulative incidence of second malignancy was 3.43%
(95% CI 0.4%-6.5%) when estimated at 10 years (Table 1).
Second malignancy diagnosis information was not
collected.
DISCUSSION
This is the ﬁrst study, to our knowledge, to prospectively
observe patients after complete resection of classic
supratentorial ependymoma. Earlier, supratentorial ana-
plastic ependymoma was considered more aggressive than
classic ependymoma and more common in older than
younger children.
The rationale for using histologic grade in treatment
stratiﬁcation was based on a blinded pathology review of 50
patients, which showed that histologic grade affected
progression-free survival (PFS; P, .001) after irradiation.17
Observation after resection was empirically recommended
by some groups, which made it a controversial option that
was not resolved by this prospective trial.18-20 Surgery alone
was an effective strategy in some patients and continues to
be used in the successor ACNS0831 trial.21
ACNS0121 is the ﬁrst prospective trial, to our knowledge, to
recommend the use of chemotherapy and second surgery
before irradiation. Trial design was inﬂuenced by data that
suggested easier tumor resection after chemotherapy and
reduction in surgical morbidity by allowing patients to heal
between resections. Chemotherapy provided time to im-
prove surgical planning or access to expert teams.
Surgical resection is the most important prognostic factor
for children with ependymoma. Children who achieve
complete resection have the highest PFS and OS rates. An
earlier series, in which second resection was systematically
performed before CRT, reported the highest rates of local
control, PFS, and OS.11 Second surgery was often feasible,
depending on location of the residual tumor.
Although the main goal for patients in stratum 2 was to use
chemotherapy to facilitate second surgery before CRT, only
No. at risk
Classic ependymoma 157 143 124 107 93 33
Anaplastic ependymoma 124 102 78 65 52 16
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39% of patients underwent second surgery, and only 56%
achieved GTR. The ACNS0831 trial was activated in
2010.21 The study randomly assigned patients to post-CRT
chemotherapy or to observation, a logical next step beyond
surgery and immediate postoperative irradiation.
The SIOP-EP-II study is testing conventional and novel
agents as front-line treatment in patients with ependy-
moma.22 Patients with no evidence of residual disease are
randomly assigned to receive 16 weeks of multiagent
chemotherapy or observation after irradiation. Patients with
residual disease receive preirradiation conventional che-
motherapy with or without methotrexate and post-CRT
conventional chemotherapy. Patients not eligible to receive
CRT because of age or other considerations receive con-
ventional chemotherapy for 1 year with or without the
histone deacetylase inhibitor valproate. To combat local
failures, patients with residual disease receive additional
irradiation, given data to suggest that escalation of the RT
dose can improve outcomes.23
A groundbreaking aspect of this study was that immediate
postoperative CRT was administered to very young chil-
dren. Rates of disease control and survival of children age
3 years or younger who achieved NTR or GTR and who
were receiving immediate postoperative CRTwere similar to
those of older children. The survival of very young children
with newly diagnosed ependymoma was higher than pre-
vious studies using chemotherapy after surgery to delay or
avoid irradiation. The landmark Pediatric Oncology Group
(POG) study POG 9233 (conducted from 1992 to 1997)
used standard or dose-intensiﬁed chemotherapy for chil-
dren with ependymoma, with radiation therapy deferred to
time of progression.6 The 5-year EFS and OS rates for the
entire POG 9233 cohort were 24.4% (95% CI, 15.3% to
33.5%) and 42.7% (95% CI, 32.1% to 53.3%), re-
spectively. In this ACNS0121 study, the 5-year EFS and OS
rates for the most favorable cohort (combined strata 3 and
4) were 68.5% (95% CI, 62.8% to 74.2%) and 86.2%
(95% CI, 81.9% to 90.5%), respectively. For the less fa-
vorable subtotal resection cohort, the 5-year EFS and OS
rates were 37.2% (95% CI, 24.9% to 49.5%) and 70.2%
(95% CI, 58.2% to 82.2%), respectively.
In ACNS0121, EFS and OS were better for older patients
than they were for those patients in the CCG9942 study
(conducted from 1995 to 1999), which included chemo-
therapy before RT for selected patients. The study reported
5-year EFS and OS rates of 57% and 71%, respectively.5 In
this ACNS0121 study, 5-year EFS and OS rates were 65%
and 83%, respectively, for the entire cohort older than age
3 years and were 71% and 85%, respectively, for those
who received immediate postoperative CRT.
Intraobserver variability in the histopathologic assessment
of ependymoma was less than expected. Survival outcomes
by tumor grade were consistent. These ﬁndings are im-
portant because the histopathologic assessment of
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FIG 5. Cumulative incidence of (A) local and (B) distant failure
for patients treated with immediate postoperative radiation
therapy (strata 3 and 4).
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ependymoma has come into question, along with the need
to incorporate and validate molecular markers.24,25
Nine distinct molecular groups of ependymoma have been
identiﬁed across the neuraxis.26 Patients with RELA fusion–
positive tumors were considered to have a poor prognosis.27
Our data conﬁrm that most supratentorial tumors have
RELA fusion. Contrary to previous reports, patients with
RELA fusion–positive tumors do not have uniformly poor
survival when treated with immediate postoperative irra-
diation.26 Prognostic signiﬁcance of 1q gain in infratentorial
ependymoma has been examined. Gain of 1q was ob-
served at diagnosis in 16 (13%) of 119 patients with
infratentorial ependymoma who received uniform CRT.28
The hazard ratio for tumor progression was 2.51, which was
highly signiﬁcant (P = .008), and conﬁrmed that 1q gain is a
marker for increased local and distant tumor progression.
Prognostic signiﬁcance of the PFA and PFB distinction was
not shown among patients who received uniformCRT. These
results will serve as an important benchmark for future
studies that propose treatment intensiﬁcation or reduction in
selected cohorts.29,30 Children with a PFA tumor who un-
dergo GTR clearly beneﬁt from CRT. Postoperative irradia-
tion for PFA should remain the backbone of current
treatment protocols. Children with PFA tumors without 1q
gain fare well with surgery and irradiation.
In summary, EFS and OS rates of very young children
treated with immediate postoperative CRT after GTR or
NTR in this study were more than twice that of children
treated using strategies that delayed the use of irradia-
tion. Survival for young children was similar to those of
older children who received front-line CRT. CRT is
conﬁrmed as an effective adjuvant therapy, irrespective
of subgrouping. RELA fusion–positive tumors comprise
the majority of supratentorial tumors, and patients with
RELA fusion–positive tumors who receive CRT do not
have a uniformly poorer survival. Patients with PFA tu-
mors without 1q gain have excellent outcomes with
surgery and CRT.
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APPENDIX
No. at risk
Second surgery 25 21 13 11 9 3
No second surgery 39 27 13 10 4 3
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(95% CI, 0.0 to 55.0)
Log-rank test:
(P = .116)
FIG A1. Event-free survival (EFS) for patients in stratum 2 who were undergoing versus not
undergoing second surgery.
No. at risk
< 3 years old 75 65 49 45 39 14 1
≥ 3 years old 206 181 153 127 107 35
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FIG A2. Event-free survival (EFS) for patients treated with immediate postoperative
radiation therapy (strata 3 and 4) by age at time of conformal radiation therapy.
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No. at risk
1q gain (absent) + PFA 60 57 51 46 38 14
1q gain (present) + PFA 14 10 7 5 4 1
FIG A3. Event-free survival (EFS) for patients with infratentorial tumors and posterior fossa
group A (PFA) classiﬁcation who were treated with immediate postoperative radiation
therapy (strata 3 and 4) according to 1q gain status.
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